Skip to content
10-K

Annual Report

Nautilus Biotechnology, Inc. NAUT

0001808805-26-000011

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 19, 2026 126.56M sh
Shares Diluted FY 2025 · Dec 31, 2025 126.26M sh
Shares Diluted FY 2025 · Dec 31, 2024 125.43M sh
Capex FY 2025 · Dec 31, 2025 $1.28M
Capex FY 2025 · Dec 31, 2024 $2.12M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$50.7M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$59.15M
Cash And Equivalents FY 2025 · Dec 31, 2025 $12.39M
Cash And Equivalents FY 2025 · Dec 31, 2024 $27.65M
Stockholders Equity FY 2025 · Dec 31, 2025 $156.97M
Stockholders Equity FY 2025 · Dec 31, 2024 $208.73M
Stockholders Equity FY 2025 · Dec 31, 2023 $265.35M
Current Liabilities FY 2025 · Dec 31, 2025 $7.95M
Current Liabilities FY 2025 · Dec 31, 2024 $7.63M
Total Liabilities FY 2025 · Dec 31, 2025 $34.14M
Total Liabilities FY 2025 · Dec 31, 2024 $34.01M
Current Assets FY 2025 · Dec 31, 2025 $105.96M
Current Assets FY 2025 · Dec 31, 2024 $132.83M
Total Assets FY 2025 · Dec 31, 2025 $191.11M
Total Assets FY 2025 · Dec 31, 2024 $242.74M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.47
Eps Diluted FY 2025 · Dec 31, 2024 −$0.56
Eps Basic FY 2025 · Dec 31, 2025 −$0.47
Eps Basic FY 2025 · Dec 31, 2024 −$0.56
Rd Expense FY 2025 · Dec 31, 2025 $41.11M
Rd Expense FY 2025 · Dec 31, 2024 $50.48M
Net Income FY 2025 · Dec 31, 2025 −$59M
Net Income FY 2025 · Dec 31, 2024 −$70.78M